Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Napoleone Ferrara

Showing results (31-40 of 195) with videos related to

Pageof 20
Sort By:
Cell and Tissue Research|September 4, 2008
VEGF inhibition: insights from preclinical and clinical studiesYongping Crawford, Napoleone Ferrara
Frontiers in Immunology|March 8, 2021
Iron Metabolism in the Tumor Microenvironment: Contributions of Innate Immune CellsWei Liang, Napoleone Ferrara
Methods in Enzymology|November 22, 2008
Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitorsYongping Crawford, Napoleone Ferrara
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Vascular endothelial growth factor signaling pathways: therapeutic perspectiveMarcin Kowanetz, Napoleone Ferrara
Trends in Pharmacological Sciences|October 20, 2009
Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapiesYongping Crawford, Napoleone Ferrara
Trends in Cardiovascular Medicine|October 3, 2003
EG-VEGF and Bv8. a novel family of tissue-selective mediators of angiogenesis, endothelial phenotype, and functionJennifer LeCouter, Napoleone Ferrara
Cardiovascular Diabetology|April 8, 2015
Inhibition of protein kinase C enhances angiogenesis induced by platelet-derived growth factor C in hyperglycemic endothelial cellsJunji Moriya, Napoleone Ferrara
Cancer Research|February 12, 2005
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studiesHans-Peter Gerber, Napoleone Ferrara
Cancer Journal (Sudbury, Mass.)|August 18, 2018
Introduction by the Guest Editors: BevacizumabNapoleone Ferrara, Daniel S Chen
Nature|December 16, 2005
Angiogenesis as a therapeutic targetNapoleone Ferrara, Robert S Kerbel
Pageof 20

Showing results (31-40 of 195) with videos related to

Sort By:
Pageof 20
Cell and Tissue Research|September 4, 2008
VEGF inhibition: insights from preclinical and clinical studiesYongping Crawford, Napoleone Ferrara
Frontiers in Immunology|March 8, 2021
Iron Metabolism in the Tumor Microenvironment: Contributions of Innate Immune CellsWei Liang, Napoleone Ferrara
Methods in Enzymology|November 22, 2008
Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitorsYongping Crawford, Napoleone Ferrara
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Vascular endothelial growth factor signaling pathways: therapeutic perspectiveMarcin Kowanetz, Napoleone Ferrara
Trends in Pharmacological Sciences|October 20, 2009
Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapiesYongping Crawford, Napoleone Ferrara
Trends in Cardiovascular Medicine|October 3, 2003
EG-VEGF and Bv8. a novel family of tissue-selective mediators of angiogenesis, endothelial phenotype, and functionJennifer LeCouter, Napoleone Ferrara
Cardiovascular Diabetology|April 8, 2015
Inhibition of protein kinase C enhances angiogenesis induced by platelet-derived growth factor C in hyperglycemic endothelial cellsJunji Moriya, Napoleone Ferrara
Cancer Research|February 12, 2005
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studiesHans-Peter Gerber, Napoleone Ferrara
Cancer Journal (Sudbury, Mass.)|August 18, 2018
Introduction by the Guest Editors: BevacizumabNapoleone Ferrara, Daniel S Chen
Nature|December 16, 2005
Angiogenesis as a therapeutic targetNapoleone Ferrara, Robert S Kerbel
Pageof 20